論文種別 | 原著(症例報告除く) |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia |
掲載誌名 | 正式名:International journal of hematology 略 称:Int J Hematol ISSNコード:09255710 |
掲載区分 | 国外 |
巻・号・頁 | 116(2),pp.199-214 |
著者・共著者 | Marumo A, Wakita S, Morita K, Oh I, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Uoshima N, Kobayashi Y, Kawata E, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Kubota Y, Kimura S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Date K, Fujiwara Y, Terada K, Yui S, Arai K, Kitano T, Miyata M, Ohashi K, Kanda Y, Yamaguchi H. |
発行年月 | 2022/04 |
DOI | 10.1007/s12185-022-03328-6 |
PMID | 35377134 |